Side effects profile in humans of 11C-(+)-PHNO, a dopamine D2/3 agonist ligand for PET

Journal of Nuclear Medicine

Volumn 51, Issue 3, 2010, Pages 496-497

  Mizrahi, Romina ^a   Houle, Sylvain ^a   Vitcu, Irina ^a   Ng, Alvina ^a   Wilson, Alan A ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 PROPYL 9 HYDROXYNAPHTHOXAZINE C 11; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LIGAND; NAXAGOLIDE; OXAZINE DERIVATIVE;

BINDING AFFINITY; DRUG EFFECT; HUMAN; IN VIVO STUDY; LETTER; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VOMITING; DRUG POTENTIATION; METABOLISM; REGRESSION ANALYSIS;

HUMANS; LIGANDS; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REGRESSION ANALYSIS;

EID: 77950364493     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.072314     Document Type: Letter

References (7)

1. 2 high-affinity state with positron emission tomography. J Med Chem. 2005;48:4153-4160.
2. 3 receptor preferring agonist in vivo. Synapse. 2006;60:485-495.
3. 11C]-(+)-PHNO. Biol Psychiatry. 2006;59:389-394.
4. 3 receptor agonist, 7-OH-DPAT, causes vomiting in the dog. Life Sci. 1995;57:PL347-PL350.
5. Grandas F, Quinn N, Critchley P, Rohan A, Marsden CD, Stahl SM. Antiparkinsonian activity of a single oral dose of PHNO. Mov Disord. 1987;2:47-51.
6. Coleman RJ, Quinn NP, Traub M, Marsden CD. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53:102-105. (Pubitemid 20067655)
7. 2-receptor agonist administered as a long-acting formulation. Mov Disord. 1990;5:298-303.